Immune-related adverse events from contemporary first-line combination therapies in metastatic renal cell carcinoma: Results from the IMDC

被引：0

作者：

Navani, V. ^{[1
]}

Lemelin, A. ^{[1
]}

Powles, T. B. ^{[2
]}

Liow, E. C. H. ^{[3
]}

Wong, S. S. L. ^{[4
]}

Meza, L. A. ^{[5
]}

Ebrahimi, H. ^{[5
]}

Saliby, R. M. ^{[6
]}

Saad, E. ^{[6
]}

Yuasa, T. ^{[7
]}

Wood, L. A. ^{[8
]}

Kollmannsberger, C. K. ^{[9
]}

Graham, J. ^{[10
]}

North, S. ^{[11
]}

Basappa, N. S. ^{[11
]}

Donskov, F. ^{[12
]}

Suarez Rodriguez, C. ^{[13
]}

Lalani, A-K. ^{[14
]}

Choueiri, T. K. ^{[6
]}

Heng, D. Y. C. ^{[1
]}

机构：

[1] Tom Baker Canc Clin, Med Oncol Dept, Calgary, AB, Canada

[2] Barts Hlth NHS Trust, Oncol Dept, St Bartholomews Hosp, London, England

[3] Monash Hlth, Med Oncol, Monash Med Ctr, Clayton, Vic, Australia

[4] Western Hlth, Med Affairs Dept, Sunshine Hosp, St Albans, Vic, Australia

[5] City Hope Comprehens Canc Ctr, Med Oncol, Duarte, CA USA

[6] Dana Farber Canc Inst, Med Oncol Dept, Boston, MA USA

[7] JFCR, Urol, Canc Inst Hosp, Koto Ku, Tokyo, Japan

[8] Dalhousie Univ, Div Med Oncol, Dept Med, Halifax, NS, Canada

[9] BC Canc Agcy Vancouver, Med Oncol Dept, Vancouver, BC, Canada

[10] Univ Manitoba, Med Oncol Dept, Fac Med Internal Med, Winnipeg, MB, Canada

[11] Univ Alberta, Med Oncol Dept, Cross Canc Inst, Edmonton, AB, Canada

[12] Aarhus Univ Hosp, Oncol Dept, Aarhus, Denmark

[13] Vall dHebron Univ Hosp, Oncol Dept, Barcelona, Spain

[14] Hamilton Hlth Sci, Genitourinary Oncol Dept, JCC Juravinski Canc Ctr, Med Oncol Div, Hamilton, ON, Canada

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.1123

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1893P

引用

页码：S1018 / S1019

页数：2

共 50 条

[31] First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Ruiz-Morales, Jose Manuel
Swierkowski, Marcin
Wells, J. Connor
Fraccon, Anna Paola
Pasini, Felice
Donskov, Frede
Bjarnason, Georg A.
Lee, Jae-Lyun
Sim, Hao-Wen
Sliwczynsk, Andrzej
Ptak-Chmielewska, Aneta
Teter, Zbigniew
Beuselinck, Benoit
Wood, Lori A.
Yuasa, Takeshi
Pezaro, Carmel
Rini, Brian I.
Szczylik, Cezary
Choueiri, Toni K.
Heng, Daniel Y. C.
EUROPEAN JOURNAL OF CANCER, 2016, 65 : 102 - 108
[32] Real-world outcomes of first-line dual immunotherapy versus combination VEGF immunotherapy in intermediate-poor risk metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Data Consortium (IMDC).
Zarba, Martin
Maj, David
Wells, Connor
Chehade, Razane El Hajj
Ozay, Zeynep Irem
Pal, Sumanta Kumar
Beuselinck, Benoit
Liow, Elizabeth Chien Hern
Alva, Ajjai Shivaram
Powles, Thomas
Bjarnason, Georg A.
Wood, Lori
Kanesvaran, Ravindran
de Velasco, Guillermo
Lee, Jae Lyun
Templeton, Arnoud J.
McKay, Rana R.
Suarez, Cristina
Choueiri, Toni K.
Heng, Daniel Yick Chin
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
[33] Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
Ikeda, Takashi
Ishihara, Hiroki
Nemoto, Yuki
Tachibana, Hidekazu
Fukuda, Hironori
Yoshida, Kazuhiko
Takagi, Toshio
Iizuka, Junpei
Hashimoto, Yasunobu
Ishida, Hideki
Kondo, Tsunenori
Tanabe, Kazunari
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (10) : 735.e9 - 735.e16
[34] Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab
Ishihara, Hiroki
Takagi, Toshio
Kondo, Tsunenori
Homma, Chie
Tachibana, Hidekazu
Fukuda, Hironori
Yoshida, Kazuhiko
Iizuka, Junpei
Kobayashi, Hirohito
Okumi, Masayoshi
Ishida, Hideki
Tanabe, Kazunari
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (06) : 355.e21 - 355.e29
[35] A Tale of Immune-Related Adverse Events With Sequential Trials of Checkpoint Inhibitors in a Patient With Metastatic Renal Cell Carcinoma
Singh, Vinit
Chu, Yvonne
Gupta, Varsha
Zhao, Charlie Weige
CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (06)
[36] Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium EDITORIAL COMMENT
Singla, Nirmish
JOURNAL OF UROLOGY, 2023, 209 (04): : 709 - 709
[37] Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma (vol 84, pg 109, 2023)
Ernst, Matthew S.
Navani, Vishal
Wells, J. Connor
Donskov, Frede
Basappa, Naveen
Labaki, Chris
Pal, Sumanta K.
Meza, Luis
Wood, Lori A.
Ernst, D. Scott
Szabados, Bernadett
McKay, Rana R.
Parnis, Francis
Suarez, Cristina
Yuasa, Takeshi
Lalani, Aly-Khan
Alva, Ajjai
Bjarnason, Georg A.
Choueiri, Toni K.
Heng, Daniel Y. C.
EUROPEAN UROLOGY, 2023, 83 (06) : E166 - E167
[38] First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An updated analysis from the International mRCC Database Consortium (IMDC).
Harshman, Lauren Christine
Kroeger, Nils
Rha, Sun Young
Donskov, Frede
Wood, Lori
Tantravahi, Srinivas Kiran
Vaishampayan, Ulka N.
Rini, Brian I.
Knox, Jennifer J.
North, Scott A.
MacKenzie, Mary J.
Yuasa, Takeshi
Srinivas, Sandy
Pal, Sumanta Kumar
Heng, Daniel Yick Chin
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[39] Immune-related myositis resulting from combination therapy of ipilimumab and nivolumab in patient with metastatic renal cell carcinoma
Okubo, Naoya
Kijima, Toshiki
Nukui, Akinori
Kamai, Takao
BMJ CASE REPORTS, 2020, 13 (09)
[40] Re: First-Line Sunitinib versus Pazopanib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Laguna, M. Pilar
JOURNAL OF UROLOGY, 2017, 197 (03): : 603 - 603

← 1 2 3 4 5 →